Life Healthcare

HEPS from continuing and discontinued operations will be between 10% and 26% lower to between 78.1c to 95.6c. It expects group revenue growth from continuing operations of between 7-13% y/y. EBITDA from continuing operations increased by between 1-6% and the margin is expected to be between 15-17% versus a prior 16.8%. Results are expected 16 November 2023.
Click here to read the SENS